Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Mantle-Cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 366 (final count)
- Started
- Jun 19, 2017
- Main results expected
- Jun 26, 2024
- Fully finished
- Jun 27, 2024
- Results posted
- Jul 22, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
Measured over: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
Measured over: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
Measured over: From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months
Progression-free Survival (PFS) (Randomization Phase)
Measured over: For an overall median time on study of 61.34 months
Complete Response (CR) Rate (Treatment-Naive Arm)
Measured over: For an overall median time on study of 40.51 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03112174 · record last updated 2025-07-22 · checked 2026-11-09 15:47 UTC